CHAMPIONS ONCOLOGY, INC. Increase (Decrease) in Deferred Charges
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Increase (Decrease) in Deferred Charges of $0 for the 12-month period ending 2020-04-30, per its 10-K filed 2020-07-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredCharges · last filed 2020-07-28
- CHAMPIONS ONCOLOGY, INC. increase (decrease) in deferred charges for fiscal 2020 was $0.00.
- CHAMPIONS ONCOLOGY, INC. increase (decrease) in deferred charges for fiscal 2019 was -$397.00K.
- CHAMPIONS ONCOLOGY, INC. increase (decrease) in deferred charges for fiscal 2018 was -$454.00K.
- CHAMPIONS ONCOLOGY, INC. increase (decrease) in deferred charges for fiscal 2017 was $0.00.
| Period end | Increase (Decrease) in Deferred Charges 12 month |
|---|---|
| 2020-04-30 | $0.00 10-K · filed 2020-07-28 |
| 2019-04-30 | -$397.00K 10-K · filed 2020-07-28 |
| 2018-04-30 | -$454.00K 10-K · filed 2019-07-29 |
| 2017-04-30 | $0.00 10-K · filed 2018-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |